EBITDA Margin (Quarterly)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

ImmunityBio, Inc. (IBRX) EBITDA Margin data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$44.21M
Net Income	$-632.78M
Cost of Goods Sold	$0.24M
Gross Profit	$43.97M
Operating Expenses	$114.00M
Operating Income	$-69.79M
Non-Operating Income/Expense	$-563.00M
Pre-Tax Income	$-632.79M
Normalized Pre-Tax Income	$-632.79M
Income after Taxes	$-632.80M
Income from Continuous Operations	$-632.80M
Consolidated Net Income/Loss	$-632.80M
Normalized Income after Taxes	$-632.80M
EBIT	$-69.79M
EBITDA	$-66.94M
Weighted-Average Shares Outstanding (Basic)	1.03B
Weighted-Average Shares Outstanding (Diluted)	1.03B
Earnings per Share (EPS) (Basic)	$-0.62
Earnings per Share (EPS) (Diluted)	$-0.62
Balance Sheet Financials
Current Assets	$452.95M
Property, Plant, and Equipment	$112.78M
Long-Term Assets	$193.68M
Total Assets	$646.64M
Current Liabilities	$67.95M
Long-Term Debt	$678.39M
Long-Term Liabilities	$1.45B
Total Liabilities	$1.52B
Common Equity	$-869.13M
Tangible Shareholders Equity	$-882.01M
Shareholders Equity	$-869.13M
Common Shares Outstanding	1.05B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-75.36M
Cash Flow from Investing Activities	$-31.65M
Cash Flow from Financial Activities	$223.93M
Beginning Cash	$89.43M
End Cash	$206.47M
Increase/Decrease in Cash	$117.04M
Stock-Based Compensation	$8.17M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.67
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-3.56
Debt to Equity Ratio	-0.78
Gross Margin	99.46%
Operating Margin	-157.88%
EBIT Margin	-157.88%
EBITDA Margin	--
Pre-Tax Profit Margin	-1431.45%
Profit Margin	-1431.44%
Free Cash Flow	$-77.14M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.07
Inventory Turnover	0.44
Receiveable Turnover	1.02
Days Sales in Receivables	88.10
Return on Equity	72.81%
Return on Tangible Equity	71.74%
Return on Assets	-97.86%
Return on Investments	331.76%
Book Value Per Share	$-0.83
Free Cash Flow per Share	$-0.08
Operating Cash Flow per Share	$-0.07

Data from Zacks Investment Research, Inc.